Literature DB >> 24275137

Targeting miR-21 enhances the sensitivity of human colon cancer HT-29 cells to chemoradiotherapy in vitro.

Jun Deng1, Wan Lei1, Jian-Chun Fu1, Ling Zhang1, Jun-He Li1, Jian-Ping Xiong2.   

Abstract

5-Fluorouracil (5-FU) is a classic chemotherapeutic drug that has been widely used for colorectal cancer treatment, but colorectal cancer cells are often resistant to primary or acquired 5-FU therapy. Several studies have shown that miR-21 is significantly elevated in colorectal cancer. This suggests that this miRNA might play a role in this resistance. In this study, we investigated this possibility and the possible mechanism underlying this role. We showed that forced expression of miR-21 significantly inhibited apoptosis, enhanced cell proliferation, invasion, and colony formation ability, promoted G1/S cell cycle transition and increased the resistance of tumor cells to 5-FU and X radiation in HT-29 colon cancer cells. Furthermore, knockdown of miR-21 reversed these effects on HT-29 cells and increased the sensitivity of HT-29/5-FU to 5-FU chemotherapy. Finally, we showed that miR-21 targeted the human mutS homolog2 (hMSH2), and indirectly regulated the expression of thymidine phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD). These results demonstrate that miR-21 may play an important role in the 5-FU resistance of colon cancer cells.
Copyright © 2014. Published by Elsevier Inc.

Entities:  

Keywords:  5-FU; CRC; Chemo-resistance; DPD; HT-29; MMR; NC; TP; TS; UTR; colorectal cancer; dihydropyrimidine dehydrogenase; hMSH2; miR-21; mismatch repair system; nonsense control; qRT-PCR; quantitative real time polymerase chain reaction; thymidine phosphorylase; thymidylate synthase; untranslated regions

Mesh:

Substances:

Year:  2013        PMID: 24275137     DOI: 10.1016/j.bbrc.2013.11.064

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  56 in total

1.  Clinical Usefulness of 5-FU Metabolic Enzymes as Predictive Markers of Response to Chemotherapy in Colorectal Cancer.

Authors:  Ion Cristóbal; Rebeca Manso; Paula González-Alonso; Juan Madoz-Gurpide; Federico Rojo; Jesús García-Foncillas
Journal:  World J Surg       Date:  2016-04       Impact factor: 3.352

2.  MiR-622 suppresses proliferation, invasion and migration by directly targeting activating transcription factor 2 in glioma cells.

Authors:  Rui Zhang; Hui Luo; Shuai Wang; Zhengxin Chen; Lingyang Hua; Hong-Wei Wang; Wanghao Chen; Yongsheng Yuan; Xiaobin Zhou; Daqian Li; Shuying Shen; Tao Jiang; Yongping You; Ning Liu; Huibo Wang
Journal:  J Neurooncol       Date:  2014-09-26       Impact factor: 4.130

3.  Emerging role of microRNAs in cancer stem cells: Implications in cancer therapy.

Authors:  Minal Garg
Journal:  World J Stem Cells       Date:  2015-09-26       Impact factor: 5.326

4.  MicroRNA-21 is Required for Hematopoietic Cell Viability After Radiation Exposure.

Authors:  Matthew V Puccetti; Clare M Adams; Tu D Dan; Ajay Palagani; Brittany A Simone; Tiziana DeAngelis; Christine M Eischen; Nicole L Simone
Journal:  Int J Radiat Oncol Biol Phys       Date:  2019-04-27       Impact factor: 7.038

5.  MicroRNA-197 influences 5-fluorouracil resistance via thymidylate synthase in colorectal cancer.

Authors:  Z Sun; N Zhou; Q Han; L Zhao; C Bai; Y Chen; J Zhou; R C Zhao
Journal:  Clin Transl Oncol       Date:  2015-06-09       Impact factor: 3.405

6.  Manipulating miRNA Expression: A Novel Approach for Colon Cancer Prevention and Chemotherapy.

Authors:  Satish Ramalingam; Dharmalingam Subramaniam; Shrikant Anant
Journal:  Curr Pharmacol Rep       Date:  2015-06-01

7.  Emerging role of microRNA-21 in cancer.

Authors:  Yin-Hsun Feng; Chao-Jung Tsao
Journal:  Biomed Rep       Date:  2016-08-26

Review 8.  Epigenetic Alterations in Colorectal Cancer: Emerging Biomarkers.

Authors:  Yoshinaga Okugawa; William M Grady; Ajay Goel
Journal:  Gastroenterology       Date:  2015-07-26       Impact factor: 22.682

Review 9.  Molecular approach to genetic and epigenetic pathogenesis of early-onset colorectal cancer.

Authors:  Gulcin Tezcan; Berrin Tunca; Secil Ak; Gulsah Cecener; Unal Egeli
Journal:  World J Gastrointest Oncol       Date:  2016-01-15

Review 10.  An update on microRNAs as colorectal cancer biomarkers: where are we and what's next?

Authors:  Yoshinaga Okugawa; Yuji Toiyama; Ajay Goel
Journal:  Expert Rev Mol Diagn       Date:  2014-08-28       Impact factor: 5.225

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.